Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Pediatric Primary IgA Nephropathy (China, Phase III, Single-Arm)
CTR20254489Phase 3Active
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Feb 2026; status: active.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20254489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254489.